Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical-related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services.
Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trials for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011, which has completed pre-clinical laboratory studies and is undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing an RNA-based FASH-CARTM cell therapy platform.
In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX) and offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with the Massachusetts Institute of Technology (MIT). This includes using the QTY code protein design technology for the development of a hemofiltration device to treat Cytokine Storm.
Furthermore, Avalon provides co-development of next-generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. It has a strategic partnership with the University of Natural Resources and Life Sciences in Vienna, Austria, to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and the coronavirus that causes COVID-19 disease.
The company also develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to the exosome industry. Avalon GloboCare Corp. is headquartered in Freehold, New Jersey.
